Press release
- for immediate release -

Title suggestion:
MIMETAS Appoints Biotech Pioneer Herbert Heyneker as Chairman of the Board

Leiden, The Netherlands – July 24, 2013 – MIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.

“Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I’ve seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering.” says Herb Heyneker, who is based in the San Francisco Bay area. “I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. Sure, I am going to contribute anything in my powers to make that revolution happen.”

Dr. Jos Joore, Chief Business Officer of MIMETAS, comments: “We are extremely pleased to have Herb on board. Herb is one of the world’s biotech pioneers. He knows what it means to create paradigm shifts in life sciences. Moreover, his executive skills and impressive network will help to launch MIMETAS technology worldwide.

About Dr. Herbert L. Heyneker
After earning his PhD from Leiden University in Holland, Herbert Heyneker moved in 1975 to San Francisco to take a postdoc in Herbert Boyer’s UCSF lab where he was involved in gene splicing and somatostatin research. Soon afterward, he joined Genentech as one of the company’s first scientists. In 1984 he moved to Genencor, Genentech spinoff to become VP of R&D. He has held positions with Eos Biotechnology, ProtoGene Laboratories, GlycoGen and Genencor. He also served on the board of directors for GenPharm and Guava Technologies in the US and in the Netherlands, IntroGene (acquired by Crucell), Pharming, Pepscan and Prosensa. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.

About MIMETAS
MIMETAS develops Organ-on-a-Chip technology for testing of new medicines. Its unique microfluidic technology enables testing of new medicines in high-throughput on miniaturized organ models. These models have better predictability compared to laboratory animals and conventional cell culture models. The basis under MIMETAS is comprised of a unique prototyping and production platform, a world-leading position in passive microfluidics and a unique value proposition based on Organ-on-a-Chip technology.
Currently, MIMETAS offers 3D culture microfluidic plates, while validating a range of organ models to be launched soon. Ultimately, the MIMETAS platform will be made available for patients to select optimal, individualized therapies. MIMETAS is based in Leiden, The Netherlands.

Contact MIMETAS
Jos Joore
CBO
+31 6 51696884
j.joore@mimetas.com